AbbVie - Q1 2026 Earnings Analysis

Performance Highlights

AbbVie delivered Q1 2026 net revenues of $15.0 billion, beating consensus expectations with 12.4% year-over-year growth, while GAAP diluted EPS of $0.39 missed estimates, falling from $0.72 in Q1 2025 due to elevated non-cash charges. The primary drag was a $2.39 billion change in fair value of contingent consideration liabilities and $744 million in acquired IPR&D and milestones expense, including a $650 million upfront payment for the RemeGen RC148 bispecific antibody license.

The single most important operating driver was the immunology franchise, where Skyrizi grew 31% to $4.48 billion and Rinvoq surged 23% to $2.12 billion, together more than offsetting continued Humira biosimilar erosion, with Humira revenues declining 39% to $688 million. Neuroscience also contributed meaningfully, with Vraylar up 18% to $905 million, Botox Therapeutic up 17% to $1.01 billion, and the migraine portfolio — Ubrelvy and Qulipta — posting combined revenues of $635 million, up 37% year-over-year.

Management Outlook and Forward Catalysts

Management's pipeline investments signal a business in active transition from Humira dependence toward a diversified, multi-franchise growth model, with the RemeGen PD-1/VEGF bispecific RC148 adding an oncology catalyst to an already expanding late-stage portfolio. The $8.0 billion senior notes issuance in March 2026 reflects management's willingness to lever the balance sheet to fund both near-term business development and longer-dated pipeline optionality.

The central investor debate centres on whether Skyrizi and Rinvoq growth trajectories can sustain revenue momentum as Humira erosion accelerates through 2026, and whether the escalating contingent consideration liability — now $27.0 billion — will continue to distort reported earnings and obscure underlying cash generation of $3.8 billion in operating cash flow this quarter.